Future trials for PDE5A and PDE9A in DMD may consider selecting subsets of DMD patients with ASD symptoms for treatment during critical periods of cerebellar circuit refinement with the inclusion of standard measures of cerebellar circuit function, such as conditioned eyeblink, as well as social behavior. The gene discussed is PDE9A; the disease is Duchenne muscular dystrophy.